The phosphatidylinositol 3-kinases (PI3K) are a family of enzymes that relay important cellular growth control signals. Recently, a large-scale mutational analysis of eight PI3K and eight PI3K-like genes revealed somatic mutations in PIK3CA, which encodes the p110A catalytic subunit of class IA PI3K, in several types of cancer, including glioblastoma multiforme. In that report, 4 of 15 (27%) glioblastomas contained potentially oncogenic PIK3CA mutations. Subsequent studies, however, showed a significantly lower mutation rate ranging from 0% to 7%. Given this disparity and to address the relation of patient age to mutation frequency, we examined 10 exons of PIK3CA in 73 glioblastoma samples by PCR amplification followed by direct DNA sequencing. Overall, PIK3CA mutations were found in 11 (15%) samples, including several novel mutations. PIK3CA mutations were distributed in all sample types, with 18%, 9%, and 13% of primary tumors, xenografts, and cell lines containing mutations, respectively. Of the primary tumors, PIK3CA mutations were identified in 21% and 17% of pediatric and adult samples, respectively. No evidence of PIK3CA gene amplification was detected by quantitative real-time PCR in any of the samples. This study confirms that PIK3CA mutations occur in a significant number of human glioblastomas, further indicating that therapeutic targeting of this pathway in glioblastomas is of value.
Introduction
Phosphatidylinositol 3-kinases (PI3K) are a family of lipid kinases involved in diverse cellular signaling pathways, including proliferation, differentiation, migration, trafficking, and glucose homeostasis (1) . Recently, Samuels et al. (2) did a large-scale mutational analysis of PI3K and PI3K-like genes in several human cancers and found somatic point mutations in 25% to 32% of colorectal cancers, glioblastomas, and gastric cancers and 3% to 8% of breast, lung, and colorectal adenomas. All of the mutations were identified in PIK3CA, which codes for a catalytic subunit of the class IA PI3K multiprotein enzyme. Mutations were found in 10 of the 20 exons of this gene, with the helical (exon 9) and kinase (exon 20) domains harboring the most mutations. Since this initial discovery, PIK3CA mutations have been described in ovarian, hepatocellular, thyroid and endometrial cancers, acute leukemia, as well as in other central nervous system malignancies (3) (4) (5) (6) (7) (8) (9) .
With respect to glioblastomas, Samuels et al. (2) first reported PIK3CA mutations in 4 of 15 (27%) samples. Since this initial description, several groups have reported a markedly lower PIK3CA mutation rate ranging from 0% to 7% (3, (10) (11) (12) . In addition, there have been no reports of the mutation frequency in pediatric glioblastomas, which may have a different molecular etiology from that of glioblastomas in adult patients. In the present study, we have aimed to determine the frequency of PIK3CA mutations and copy number in a cohort of 73 glioblastoma samples derived from adult and pediatric primary tumors, xenografts, and cell lines. exons in 73 glioblastoma samples identified 12 missense mutations in 11 (15%) samples (Table 1) . PIK3CA mutations were found in 7 of 38 (18%), 1 of 11 (9%), and 3 of 24 (13%) primary tumors, xenografts, and cell lines, respectively (Fig. 1A) . Corresponding normal tissue was available for each primary glioblastoma sample, and in all cases, the mutations were somatic. Mutations were identified in exons 1, 4, 7, 9, and 20. One mutation was found in exon 1 (G263A, R88Q), three in exon 4 (C892A, P298T; C928T, R310C; T1031G, V344G), one in exon 7 (G1357A, E453K), two in exon 9 (G1624A, E542K; G1633A, E545K), and five in exon 20 (A3062G, Y1021C; G3129T, M1043I; A3131G, N1044S; C3139T, H1047Y; G3145A, G1049S). One sample harbored two mutations, C892A, P298T and A3062G, A1021C. Representative sequence chromatograms are shown in Fig. 2 .
The 38 primary glioblastoma samples examined in this study were derived from both pediatric (ages V21 years) and adult patients. Overall, somatic missense PIK3CA mutations were present in 7 of 38 (18%) of the total primary tumor samples examined. Fourteen samples were derived from pediatric patients, and 24 samples were obtained from adult patients. PIK3CA mutations were found in 3 of 14 (21%) and 4 of 24 (17%) pediatric and adult glioblastoma samples, respectively (Fig. 1B) .
To determine if PIK3CA gene amplification was present in the samples examined, quantitative real-time PCR was done. No evidence of significant gene amplification (>4-fold) was found in any glioblastoma sample. Figure 3 illustrates the number of PIK3CA gene copies for each primary adult and pediatric glioblastoma sample, xenograft, and cell line. Samples of squamous cell carcinoma of the lung were included as a positive control with PIK3CA amplification (>4-fold) detected in 3 of 14 samples.
Discussion
In this study, 10 exons of PIK3CA were evaluated in 73 glioblastoma samples for mutations. Twelve missense mutations in the PIK3CA gene were identified in 11 samples with an overall mutation rate of 15% (Table 1) . PIK3CA mutations were found in 18% of primary tumor samples, 9% of xenografts, and 13% of cell lines examined; mutations were found in 17% and 21% of the adult and pediatric primary tumor samples, respectively. Four of the 12 mutations, C892A, C928T, T1031G, and A3131G, are novel. Four additional mutations, G1357A, A3062G, G3129T, and C3139T, although described in other malignancies (2, 6), have not yet been reported in glioblastomas. The remaining mutations in exons 1, 9, and 20 have been described previously in glioblastomas (2, 3, 10) . For each mutated sample, corresponding matched normal DNA, when available, was sequenced to verify that the mutation was somatic. Eight PIK3CA mutations were identified in seven of the primary tumor samples examined. Corresponding normal matched DNA was available for each of these primary samples; in each case, the mutations, including three of the novel mutations (P298T, R310C, and N1044S), were somatic. With respect to the novel mutation at amino acid position 1,044, a mutation has been reported (T3132A), which changes the amino acid at that position from an N to K (13) . In our study, we found a somatic missense mutation at nucleotide position 3,131, which resulted in an N to S change at amino acid position 1,044. Four missense mutations (V344G, E453K, E542K, and H1047Y) were identified in xenografts and cell lines, samples for which no corresponding normal DNA was available. Three of these four mutations have been previously identified in other malignances (E453K, E542K, and H1047Y; refs. 2, 4, 13) and/or glioblastoma (E542K; ref. 10). In the previous reports, these mutations were found to be somatic mutations and thus it is likely in our current study that these mutations represent acquired changes. One novel mutation (V344G) observed in a sample for which there was no matched normal DNA was not identified in any DNA sample from our study or the initial large PIK3CA mutation report (2) and may either be a mutation or a rare polymorphism.
In the initial large-scale mutational analysis of PIK3CA, Samuels et al. (2) investigated all 20 exons of PIK3CA in several tumor types by PCR amplification and direct sequencing. Although >75% of alterations occurred in exons 9 and 20, mutations were observed in 10 of the 20 exons. In that study, the authors reported PIK3CA mutations in 4 of 15 (27%) glioblastomas. Since that initial report, several additional studies have also investigated glioblastomas for PIK3CA mutations (3, (10) (11) (12) and reported a significantly lower PIK3CA mutation rate (V7%; Table 2 (11) examined all 20 exons of PIK3CA by single-strand conformational polymorphism (SSCP) analysis and direct sequencing of exons 9 and 20; no somatic mutation was found in 30 glioblastomas. Two additional studies examining 20 (10) and 10 (12) exons of PIK3CA by SSCP found mutations in 5 of 70 (7%) and 5 of 97 (5%) samples, respectively. In the current study, we investigated 10 exons of PIK3CA, previously shown to harbor mutations, by PCR amplification and direct DNA sequencing and found mutations in 11 of 73 (15%) samples. Several factors, which are discussed below, can account for the disparity between the current study and initial report of PIK3CA mutations in glioblastoma with mutation rates of 15% and 27%, respectively, and numerous other studies (3, (10) (11) (12) reporting a PIK3CA mutation rate of <7%.
Although >75% of mutations reported in the initial study by Samuels et al. (2) were in exons 9 and 20, only one of the four (25%) mutations reported in glioblastoma samples was in those two exons. In our study, exon 20 was the most frequently affected exon with 45% of samples with mutations containing mutations within this exon. Sixty-four percent of samples with mutations possessed mutations in exons 9 and 20. Analysis of the current study in combination with others examining at least the 10 exons in which PIK3CA mutations were originally described (2, 10-12) reveals that 56% (14 of 25) of glioblastoma samples with PIK3CA mutations contain a mutation in either exon 9 or 20. Thus, studies examining only exons 9 and 20 are likely to underestimate the mutation rate. It is also possible that our mutation rate of 15% may be an underestimate if any of the tumor samples in our study contained mutations within the 10 exons not examined. Indeed, PIK3CA mutations have been described in non -central nervous system malignancies in exons that were not investigated in this study, such as exon 6 and possibly exon 14 (4). There is a significant amount of variability reported in the PIK3CA mutation rate in glioblastomas even in the studies examining at least the 10 exons in which PIK3CA mutations were originally described (2), ranging from 0% to 27% (2, 10-12). One possible explanation for this range in the mutation rate is the technique used to identify the mutations. The three studies using SSCP to evaluate PIK3CA exons (10-12) have found lower mutation rates (0-7%) than the initial study (2) in which all 20 exons were PCR amplified and directly sequenced. This is not surprising as SSCP screening is a less sensitive technique for mutation detection and underestimates the true mutation rate (14, 15) . Thus, the studies using SSCP may underestimate the PIK3CA mutation rate in glioblastomas (10) (11) (12) . Combining the initial report by Samuels et al. (2) and the current study (which examined nonoverlapping samples), our best estimate for the PIK3CA mutation rate in glioblastoma patients of all ages is 17% (15 of 88).
Several of the mutations found in our study (E542K, E545K, and M1043I) are oncogenic or increase kinase activity, albeit in nongliomatous systems (16) (17) (18) (19) (20) . Another mutation that has been studied functionally (H1047R; refs. [16] [17] [18] [19] [20] was not found in our study; however, we found a mutation that changed the amino acid at the same position (H1047Y). Thus, for many mutations in the current study, there are data supporting a functional role in oncogenesis.
Interestingly, one novel mutation (P298T) was found in a pediatric sample, which contained two mutations, one in exon 4 and one in exon 20. Although the significance of this double mutant is unknown, PIK3CA double mutants have previously been described (2, 6, 13, 21) . In the study by Samuels et al. (2) , each of seven tumors contained two somatic alterations; several other groups have also reported double PIK3CA mutations (6, 13, 21). Although not specified in Samuels et al. (2) , each of the double mutants described by these other groups (6, 13, 21) , like the current case, contained one mutation in exon 20. One possible explanation for double mutations is that only one mutation is functional. This is supported in part by the observation that the only double mutation sample from our study was found to exhibit lowlevel microsatellite instability (22) . The mismatch repair instability within these tumors increases not only the chances of point mutations that activate oncogenes or inactivate tumor suppressors but also the background mutation rate in these genomes.
In addition to gene mutations, another mechanism of oncogenic activation involves gene amplification. Many studies, using various techniques, have investigated PIK3CA gene amplification in glioblastomas with somewhat differing results. Hui et al. (23) PIK3CA gene copy number gains in 9 (64.3%). Mizoguchi et al. (24) investigated 10 glioblastoma samples with fluorescence in situ hybridization and reported one case with an extra copy of PIK3CA. No amplification of PIK3CA, however, was detected in glioblastoma samples using a duplex PCR assay (12, 25) . In our study and the study reported by Broderick et al. (3) , no evidence of significant PIK3CA gene amplification was observed in 73 and 50 glioblastoma samples by quantitative PCR analysis, respectively. In summary, our results confirm previous findings of PIK3CA mutations in human glioblastomas. In this study, we report that 15% of glioblastomas possess PIK3CA mutations. Moreover, we show that PIK3CA mutations are prevalent in glioblastomas from both pediatric and adult patients. As such, therapeutics targeting this pathway may be beneficial to both adult as well as pediatric patients with the diagnosis of glioblastoma.
Materials and Methods

Tumor Samples
DNA was extracted from glioblastoma primary tumor samples (n = 38), xenografts (n = 11), and cell lines (26) , and the acquisition and use of the specimens were approved by the institutional review board.
PCR, Sequencing, and Mutational Analysis
Exons 1, 2, 4, 5, 7, 9, 12, 13, 18, and 20 were individually amplified from genomic DNA using PCR primers and conditions described previously (2) . The amplified products were sequenced by Agencourt Bioscience Corp. (Beverly, MA) using a custom sequencing primer that was complementary to an internal region of the PCR amplicon. Sequence traces were analyzed to identify potential genomic alterations using the Mutation Surveyor software package (SoftGenetics, State College, PA). All cases with mutations were verified by repeat PCR amplification and sequencing. Genomic DNA from corresponding normal brain tissue or peripheral blood was isolated and sequenced to confirm the somatic nature of the mutations in primary tumor samples.
Quantitative Real-time PCR
Copy number was determined by quantitative real-time PCR on an iCycler apparatus (Bio-Rad, Hercules, CA). Tumor DNA content was normalized to that of Line-1, a repetitive element whose copy number per haploid genome is similar among normal and neoplastic tissues. All PCR amplifications were carried out in triplicate, and the threshold cycle numbers were averaged. The following primers were used: PIK3CA, 5 ¶-TCAGATTTACGGCAAGATATGC-3 ¶ (forward) and 5 ¶-TGCCTTACTGGTTACCTACCG-3 ¶ (reverse); Line-1, 5 ¶-AAAGCCGCTCAACTACATGG-3 ¶ (forward) and 5 ¶-TGCTTTGAATGCGTCCCAGAG-3 ¶ (reverse). Real-time PCR conditions and copy number calculations were done as described previously (27) .
